Tempest Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
26/03/2025 11:24
Tempest Therapeutics Inc TPST.OQ TPST.O is expected to show no change in quarterly revenue when it reports results on March 28 (estimated) for the period ending December 31 2024 ‚ÄčLSEG's mean analyst estimate for Tempest Therapeutics Inc is for a loss of 25 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč Wall Street's median 12-month price target for Tempest Therapeutics Inc is $10.00‚Äč, above‚Äč its last closing price of $0.82. ‚Äč‚Äč‚Äč Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč
| QUARTER ENDING | STARMINESMARTESTIMATE¬ģ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Sep. 30 2024 | -0.35 | -0.36 | -0.41 | Missed | -13.3 |
| Jun. 30 2024 | -0.44 | -0.40 | -0.42 | Missed | -4.2 |
| Mar. 31 2024 | -0.38 | -0.37 | -0.36 | Beat | 3.8‚Äč |
| Dec. 31 2023 | -0.37 | -0.39 | -0.38 | Beat | 1.5 |
| ‚Äč‚ÄčSep. 30 2023 | -0.56 | -0.57 | -0.48 | Beat | 16.2 |
| Jun. 30 2023 | -0.55 | -0.52 | -0.54 | Missed | -4.3‚Äč |
| Mar. 31 2023 | -0.65 | -0.64 | -0.55 | Beat | 14.4 |
| Dec. 31 2022 | -0.76 | -0.63 | Beat | 17 |
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T